Welcome to our dedicated page for Precipio news (Ticker: PRPO), a resource for investors and traders seeking the latest updates and insights on Precipio stock.
Precipio, Inc. reports developments from its specialty cancer diagnostics business, which focuses on diagnostic products and services for cancer, including hematologic malignancies. Company updates commonly address performance in the Pathology Services Division and Products Division, customer and laboratory workflow trends, shareholder update calls, and balance sheet actions tied to debt, warrants, and common-stock financing arrangements.
Precipio news also covers its proprietary diagnostic technologies, including the Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia, study publications, scientific meeting presentations, and collaborations involving clinical laboratories and cancer centers. Operational disclosures may include cybersecurity response, service continuity, and the company’s use of laboratory-developed technologies that are validated clinically and commercialized for the broader laboratory market.
Precipio (NASDAQ: PRPO) is urging shareholders to instruct their brokers to vote their shares immediately for the 2026 annual shareholders meeting. Votes must be received by 11:59 p.m. ET on June 14, 2026 for the meeting scheduled on June 15, 2026.
About 42% of shares have been voted; at least 50% is required to reach quorum. According to Precipio, failure to reach quorum could force an adjournment and reconvening of the meeting, leading to high additional costs.
Precipio (NASDAQ: PRPO) will present at the Planet MicroCap Las Vegas 2026 conference on Wednesday, June 17, 2026, at 9:00 AM local time (12:00 PM EST) at the Bellagio Resort & Hotel.
CEO Ilan Danieli and COO Zaki Sabet will host the presentation, take questions, and participate in 1x1 investor meetings, with a live webcast available for remote attendees.
Precipio (NASDAQ: PRPO) reported Q1 2026 revenue of $6.71M, slightly above $6.69M in Q4 2025 and up from $4.93M in Q1 2025. Pathology revenue was $6.05M and product revenue $0.66M, impacted by delayed shipments shifting sales to Q2.
Net loss (GAAP) was $1.4M versus $0.9M a year earlier. Adjusted EBITDA was a loss of about $0.2M compared with a $0.1M loss in Q1 2025 and $0.96M positive in Q4 2025. Cash flow from operations was positive $60K, with total cash burn of $47K.
Precipio (NASDAQ:PRPO), a specialty cancer diagnostics company, reported that 2025 management stock options vested after its share price rose over 400% from about $6.06 to a 10-day VWAP above $30.30.
Precipio also adopted similar market-based vesting for 2026 options, and booked a Q1 2026 non-cash stock-compensation expense of $800,000.
Precipio (NASDAQ: PRPO) will host a Q1-2026 shareholder update call on May 18, 2026 at 5:00 PM ET. The call will cover the company’s core businesses and include a first-time moderated live Q&A for investors.
Participants must identify themselves to enter the Q&A; advance questions may be emailed to investors@precipiodx.com. Dial-in: 646.307.1865. A replay will be available about 24 hours after the call on the Investors page.
Precipio (NASDAQ: PRPO) will hold a Q4 and year-end 2025 shareholder update call on April 2, 2026 at 5:00 PM ET. The call will cover updates on the company’s core businesses and allow advance questions by email to investors@precipiodx.com.
Dial-in is 646.307.1865; a replay will be available about 24 hours after the call on the company’s Investors page.
Precipio (NASDAQ: PRPO) announced publication of a joint study with Memorial Sloan-Kettering Cancer Center (Mar 10, 2026) validating its Bloodhound BCR::ABL1 RT-PCR assay for CML.
The study analyzed 895 samples, found 25% of patients harbored multiple BCR::ABL1 isoforms, and reports assay sensitivity to 0.001%.
The assay quantifies all four clinically relevant isoforms (p190, p210, p230, p203) on a single plate and applies the International Scale, enabling standardized, automated MRD monitoring across lab settings.
Precipio (NASDAQ: PRPO) reported preliminary unaudited 2025 results: revenues $24.0M (up 30% YoY), Q4-2025 revenue $6.7M (up 23% YoY), Adjusted EBITDA of $1.23M for 2025 and $0.95M for Q4-2025, and positive operating cash flow of $688K for 2025.
The company said unusual items tied to Change Healthcare transactions and the Employee Retention Credit affected cash; a shareholder call is planned in early April after the 10-K filing for more detail.
Precipio (NASDAQ: PRPO) reported major balance-sheet cleanup on Jan 15, 2026. The company repaid a $1.1 million advance from Change Healthcare and now carries less than $80,000 of long-term debt (a Connecticut DECD loan amortized at $3,000/month with 3.25% interest, due May 2028). All financing warrants from the 2023 raise have been exercised; only 10,000 vendor warrants remain outstanding (strike $60, exp. Feb 2027). Management cites improved profitability and reduced financial risk for shareholders.
Precipio (NASDAQ: PRPO) will present a joint study with Memorial Sloan Kettering at the 2025 ASH meeting showing results from 895 patient samples evaluating Precipio’s BCR::ABL1 assay. The study reports superior assay performance and concordance with two leading platforms, plus improvements in patient care and laboratory workflows. The poster presentation and results discussion are scheduled for December 8, 2025, 6:00–8:00 PM at OCCC West Halls B3-B4.